Table 4.

Linear regression analysis between total change in WMH volume (cm3) and hormones, model was fit without interaction between treatment group and APOE status.

	FSH		LH		E1		E2
	Est (95% CI)	P	Est (95% CI)	P	Est (95% CI)	P	Est (95% CI)	P
Intercept	−5.22 (−18.2, 7.72)	0.42	−6.66 (−20.2, 6.91)	0.33	−7.03 (−19.7, 5.66)	0.27	−6.50 (−19.6, 6.60)	0.33
Hormone	0.005 (0.001, 0.01)	0.02	0.005 (−0.006, 0.02)	0.37	−0.004 (−0.008, −0.001)	0.01	−0.004 (−0.008, 0.001)	0.09
o-CEE	0.55 (0.19, 0.90)	0.003	0.38 (0.04, 0.71)	0.03	0.66 (0.26, 1.06)	0.001	0.42 (0.09, 0.76)	0.01
tE2	0.48 (0.11, 0.85)	0.01	0.31 (−0.04, 0.65)	0.08	0.36 (0.03, 0.69)	0.03	0.40 (0.04, 0.77)	0.03
APOE	0.17 (−0.14, 0.48)	0.27	0.18 (−0.14, 0.51)	0.27	0.17 (−0.13, 0.48)	0.26	0.18 (−0.13, 0.50)	0.25
Smoker	0.17 (−0.11, 0.46)	0.23	0.21 (−0.08, 0.50)	0.15	0.20 (−0.08, 0.48)	0.17	0.21 (−0.08, 0.49)	0.16
TIV	0.73 (−1.06, 2.51)	0.42	0.93 (−0.94, 2.80)	0.32	0.98 (−0.77, 2.72)	0.27	0.90 (−0.90, 2.70)	0.32

Abbreviations; oCEE = oral conjugated equine estrogens, tE2 = transdermal estradiol, FSH = follicle stimulating hormone, LH = luteinizing hormone, E1 = estrone, E2 = estradiol, TIV = total intracranial volume